21 May 2009
Anemia prevalence and a possible role of hepcidin in its pathogenesis in kidney allograft recipients
J Malyszko, J Malyszko, M MysliwiecAnn Transplant 2009; 14(1): 48-49 :: ID: 880376
Abstract
Hepcidin is a small defensin-like peptide whose production by hepatocytes is modulated in response to anaemia, hypoxia or infl ammation. We studied hepcidin correlations with markers of iron status, erythropoietin therapy and markers of inflammation in 100 prevalent kidney allograft recipients-Tx. In addition, prevalence of anaemia and its relation to hepcidin was also assessed. Soluble receptor of transferrin-sTfR hsCRP, TNF alpha, IL-6, prohepcidin and hepcidin were measured using commercially available kits.According to WHO definition, prevalence of anaemia was 28%. In anaemic Tx we found a significantly higher serum creatinine, serum prohepcidin, hepcidin, CRP, TNF alpha, IL-6, ferritin, proteinuria, higher use of rapamycin (n=8), and significantly lower use of CSA, lower CSA concentration, lower cholesterol, lower haemoglobin, lower eGFR (MDRD). Serum prohepcidin correlated significantly with creatinine, GFR, time after transplantation, albumin, hsCRP, IL-6 and TNF alpha, whereas hepcidin-25 correlated with serum iron, ferritin, CRP, IL-6, haemoglobin, TSAT, creatinine, GFR. Multiple regression analysis showed that prohepcidin was independently related only to GFR and ferritin. In multiple regressions analysispredictors of serum hepcidin were eGFR, TSAT and hsCRP explaining 79% of the variation of hepcidin.
Conclusions: Prevalence of anaemia is relatively high in population of kidney allograft recipients and not adequately treated (mainly due to reimbursement regulations). Elevated hepcidin levels in kidney transplant recipients may be due to low grade inflammation, frequently encountered in this population and mainly to impaired renal function, but it does not seem to be a major pathogenetic factor of anaemia in this population.
Keywords: Kidney Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






